Mats Wahlstrom Buys 5,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Mats Wahlstrom purchased 5,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were purchased at an average price of $4.55 per share, for a total transaction of $22,750.00. Following the completion of the purchase, the director now directly owns 15,727 shares of the company’s stock, valued at $71,557.85. This represents a 46.61 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Mats Wahlstrom also recently made the following trade(s):

• On Wednesday, November 20th, Mats Wahlstrom acquired 2,040 shares of TriSalus Life Sciences stock. The stock was acquired at an average cost of $4.16 per share, with a total value of $8,486.40.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI opened at $4.32 on Wednesday. TriSalus Life Sciences, Inc. has a one year low of $3.61 and a one year high of $10.42. The company has a 50-day simple moving average of $4.24 and a 200-day simple moving average of $5.49. The stock has a market capitalization of $131.73 million, a price-to-earnings ratio of -1.73 and a beta of 0.49.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Northland Securities initiated coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price on the stock. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Canaccord Genuity Group dropped their price objective on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, Roth Mkm began coverage on TriSalus Life Sciences in a research report on Monday, November 11th. They issued a “buy” rating and a $11.00 target price for the company. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, TriSalus Life Sciences has a consensus rating of “Buy” and a consensus price target of $12.08.

Institutional Trading of TriSalus Life Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Duquesne Family Office LLC grew its stake in shares of TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after purchasing an additional 110,966 shares during the last quarter. Highbridge Capital Management LLC purchased a new position in TriSalus Life Sciences in the 2nd quarter valued at $1,184,000. Geode Capital Management LLC increased its stake in TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares during the period. Wolverine Asset Management LLC purchased a new position in TriSalus Life Sciences during the 2nd quarter worth $240,000. Finally, MSD Partners L.P. acquired a new stake in shares of TriSalus Life Sciences in the 3rd quarter worth $184,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.